JP7721568B2 - 新皮質層５グルタミン酸作動性ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物 - Google Patents

新皮質層５グルタミン酸作動性ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物

Info

Publication number
JP7721568B2
JP7721568B2 JP2022563930A JP2022563930A JP7721568B2 JP 7721568 B2 JP7721568 B2 JP 7721568B2 JP 2022563930 A JP2022563930 A JP 2022563930A JP 2022563930 A JP2022563930 A JP 2022563930A JP 7721568 B2 JP7721568 B2 JP 7721568B2
Authority
JP
Japan
Prior art keywords
ehgt
seq
sequence
artificial
coding sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022563930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522708A5 (https=
JP2023522708A (ja
Inventor
デイグル，ターニャ
グレイバック，ルーカス・ティー
カルムバック，ブライアン・エドワード
レイン，エドワード・セバスチャン
リーバイ，ボアズ・ピー
ミッチ，ジョン・ケイ
セデノ・コルテス，アドリアナ・エステラ
タシッチ，ボシリカ
ティン，ジョナサン
ゼン，ホンクイ
Original Assignee
アレン インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレン インスティテュート filed Critical アレン インスティテュート
Publication of JP2023522708A publication Critical patent/JP2023522708A/ja
Publication of JP2023522708A5 publication Critical patent/JP2023522708A5/ja
Priority to JP2025127056A priority Critical patent/JP2025163106A/ja
Application granted granted Critical
Publication of JP7721568B2 publication Critical patent/JP7721568B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
JP2022563930A 2020-04-21 2021-04-21 新皮質層５グルタミン酸作動性ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物 Active JP7721568B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025127056A JP2025163106A (ja) 2020-04-21 2025-07-30 新皮質層５グルタミン酸作動性ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013342P 2020-04-21 2020-04-21
US63/013,342 2020-04-21
PCT/US2021/028489 WO2021216778A2 (en) 2020-04-21 2021-04-21 Artificial expression constructs for selectively modulating gene expression in neocortical layer 5 glutamatergic neurons

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025127056A Division JP2025163106A (ja) 2020-04-21 2025-07-30 新皮質層５グルタミン酸作動性ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物

Publications (3)

Publication Number Publication Date
JP2023522708A JP2023522708A (ja) 2023-05-31
JP2023522708A5 JP2023522708A5 (https=) 2024-02-27
JP7721568B2 true JP7721568B2 (ja) 2025-08-12

Family

ID=78269916

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022563930A Active JP7721568B2 (ja) 2020-04-21 2021-04-21 新皮質層５グルタミン酸作動性ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物
JP2025127056A Pending JP2025163106A (ja) 2020-04-21 2025-07-30 新皮質層５グルタミン酸作動性ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025127056A Pending JP2025163106A (ja) 2020-04-21 2025-07-30 新皮質層５グルタミン酸作動性ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物

Country Status (7)

Country Link
US (1) US20230159952A1 (https=)
EP (1) EP4139462A4 (https=)
JP (2) JP7721568B2 (https=)
KR (1) KR20230002788A (https=)
AU (1) AU2021261359A1 (https=)
CA (1) CA3175993A1 (https=)
WO (1) WO2021216778A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4413142A4 (en) * 2021-10-05 2025-11-05 Allen Inst ARTIFICIAL EXPRESSION CONSTRUCTIONS TO MODULATE GENE EXPRESSION IN THE CEREBELLUM AND IN A SECONDARY CELL TYPE
JP2025520385A (ja) * 2022-06-13 2025-07-03 アレン インスティテュート 中枢神経系の非神経細胞において遺伝子発現を調節するための人工発現コンストラクト
WO2025059552A1 (en) * 2023-09-14 2025-03-20 Allen Institute Artificial expression constructs for modulating gene expression in the basal ganglia
WO2025179180A1 (en) * 2024-02-23 2025-08-28 Allen Institute Artificial expression constructs for modulating gene expression in motor neurons and cerebellar neurons

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
US10973930B2 (en) * 2016-02-18 2021-04-13 The Penn State Research Foundation Generating GABAergic neurons in brains
WO2020076614A1 (en) * 2018-10-08 2020-04-16 Allen Institute Artificial expression constructs for selectively modulating gene expression in interneurons
AU2019357039B2 (en) * 2018-10-12 2025-10-09 Genzyme Corporation Generation of improved human pah for treatment of severe PKU by liver-directed gene replacement therapy
US20220249703A1 (en) * 2019-02-15 2022-08-11 Allen Institute Artificial expression constructs for selectively modulating gene expression in selected neuronal cell populations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRAYBUCK Lucas T. et al.，Prospective, brain-wide labeling of neuronal subclasses with enhancer-driven AAVs，bioRiv，2019年01月31日，<URL: https://www.biorxiv.org/content/10.1101/525014v2>
Mouse DNA sequence from clone RP23-29H22 on chromosome 4, complete sequence，GenBank, Accession No. AL606962，[retrived on 2025.02.18]，2012年，<URL: https://www.ncbi.nlm.nih.gov/nucleotide/AL606962.22?re port=genbank&log$=nuclalign&blast_rank=1&RID=V8JCSC6G013>

Also Published As

Publication number Publication date
US20230159952A1 (en) 2023-05-25
CA3175993A1 (en) 2021-10-28
WO2021216778A2 (en) 2021-10-28
EP4139462A2 (en) 2023-03-01
WO2021216778A3 (en) 2021-12-16
AU2021261359A1 (en) 2022-12-08
JP2025163106A (ja) 2025-10-28
EP4139462A4 (en) 2025-03-12
JP2023522708A (ja) 2023-05-31
KR20230002788A (ko) 2023-01-05

Similar Documents

Publication Publication Date Title
JP7695192B2 (ja) 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物
JP7721568B2 (ja) 新皮質層５グルタミン酸作動性ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物
JP2026001073A (ja) 非神経脳細胞での遺伝子発現を選択的に調節する人工発現構築物
JP2026021417A (ja) 抑制性新皮質ニューロンにおいて遺伝子発現を選択的に調節する人工発現構築物
US20250235550A1 (en) Artificial expression constructs for modulating gene expression in the cerebellum and a secondary cell type
US20240254514A1 (en) Artificial expression constructs for modulating gene expression in neurons within the thalamus
KR20250142388A (ko) 척수 내의 세포에서 유전자 발현을 조정하기 위한 인공 발현 구축물
US20240018543A1 (en) Artificial expression constructs for modulating gene expression in chandelier cells
AU2023293067A1 (en) Artificial expression constructs for modulating gene expression in non-neuronal central nervous system cells
WO2022212585A1 (en) Artificial expression constructs for modulating gene expression in claustrum neurons
US20250041454A1 (en) Artificial expression constructs for modulating gene expression in neocortical layer 4 or layer 5 intratelencephalic neurons

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250730

R150 Certificate of patent or registration of utility model

Ref document number: 7721568

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150